Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 11%

Bulls say

Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using their proprietary PROTAC technology. The company's partnerships with large pharmaceutical companies, along with their promising clinical candidates in oncology and neuroscience, position them for strong growth potential. The recent Rigel Pharmaceuticals partnership for their lead drug candidate, VEPPANU, removes a key commercial overhang and provides necessary capital for their pipeline. With several upcoming data catalysts and a favorable entry point for investors, the company has a bright outlook.

Bears say

Arvinas is a clinical-stage biotechnology company with a promising protein degradation platform that aims to treat a variety of diseases. However, the lack of profitability and uncertainty surrounding their product candidates, particularly ARV-806, indicate that there may be regulatory and commercialization challenges ahead, leading to a negative outlook on the stock. Investors should closely monitor the company's financial performance and the progress of their clinical development program.

Arvinas Inc (ARVN) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 9 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.